KRTL HOLDING GROUP INC. REPORTS THIRD QUARTER 2025 RESULTS (UNAUDITED) AND FILES PCAOB-AUDITED 2024 AND 2023 FINANCIAL STATEMENTS

Core Viewpoint - KRTL Holding Group Inc. has completed a PCAOB audit of its financial statements for the years ended December 31, 2024, and 2023, with no changes to previously reported unaudited amounts, and reported financial results for the three and nine months ended September 30, 2025, including contributions from its newly acquired subsidiary, Sigma [1][2][4]. Financial Performance - For the three months ended September 30, 2025, total revenues amounted to $1,815,781, with $1,752,656 generated from 28 days of operations of the Sigma subsidiary [2]. - Sigma generated approximately $19.7 million in revenue with a gross margin of 57% for the six months ended September 30, 2025, indicating an annualized revenue run rate of about $40 million [3]. Asset and Equity Position - As of September 30, 2025, KRTL Holding Group reported total assets of approximately $23.8 million and total shareholders' equity of $8.7 million [4]. Strategic Initiatives - The acquisition of Sigma is viewed as a scalable revenue base, with plans to expand distribution of pharmaceuticals and nutraceuticals internationally, including a potential entry into the U.S. market [3]. - The completion of the PCAOB audit positions the Company to pursue an uplisting to a higher-tier trading venue, which could enhance visibility and improve trading liquidity [4]. Company Overview - KRTL Holding Group operates through subsidiaries KRTL Biotech, Inc. and KRTL International Corp., leveraging strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value [6].